In the case of Hepatitis C, the identification of the HCV NS3 protease as a therapeutic target led to the application of a primary screening strategy to well-known compounds approved by FDA initially designed for other therapeutic purposes [6]. Here, KRAS is linked to hepatitis C virus infection.